The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.

In a deal announced Thursday, CAMP4 said it will receive $17.5 million upfront from GSK and will be eligible for development and commercial milestone payments as well as tiered royalties on ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The committee recommended the combo for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations based on data from the MARIPOSA trial.

The firm is submitting data showing that a one-time treatment with ST-920 led to a positive annualized estimated glomerular filtration rate slope.

The company said the combo could help overcome resistance to EGFR inhibitors in patients whose tumors harbor the mutation.

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.